Target Price | $61.20 |
Price | $52.71 |
Potential |
16.11%
register free of charge
|
Number of Estimates | 14 |
14 Analysts have issued a price target Pieris Pharmaceuticals, Inc. 2026 .
The average Pieris Pharmaceuticals, Inc. target price is $61.20.
This is
16.11%
register free of charge
$94.50
79.28%
register free of charge
$49.49
6.11%
register free of charge
|
|
A rating was issued by 16 analysts: 15 Analysts recommend Pieris Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Pieris Pharmaceuticals, Inc. stock has an average upside potential 2026 of
16.11%
register free of charge
|
Analyst | Rating | Action | Date |
---|---|---|---|
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 15 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 15 2025 |
Raymond James |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
LifeSci Capital |
Locked
➜
Locked
|
Locked | Aug 04 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Jul 21 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | May 16 2025 |
Analyst Rating | Date |
---|---|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 19 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 15 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 15 2025 |
Locked
Raymond James:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
LifeSci Capital:
Locked
➜
Locked
|
Aug 04 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Jul 21 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
May 16 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.